Hepatocyte growth factor both prevents and ameliorates the symptoms of dermal sclerosis in a mouse model of scleroderma

Gene Therapy

Volumn 11, Issue 2, 2004, Pages 170-180

  Wu, M H ^a   Yokozeki, H ^a   Takagawa, S ^a   Yamamoto, T ^a   Satoh, T ^a   Kaneda, Y ^b   Katayama, I ^c   Nishioka, K ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NAGASAKI UNIVERSITY   (Japan)

Author keywords

Bleomycin(BLM); Hepatocyte growth factor (HGF); Liposome; Lung fibrosis; Scleroderma; Systemic sclerosis (SSc)

Indexed keywords

ANTIMETABOLITE; BLEOMYCIN; COMPLEMENTARY DNA; LIPOSOME; MESSENGER RNA; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROSIS; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE THERAPY; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAMUSCULAR DRUG ADMINISTRATION; LUNG; LUNG FIBROSIS; METABOLISM; METHODOLOGY; MORPHEA; MOUSE; MOUSE STRAIN; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCLERODERMA; SENDAI VIRUS; SKELETAL MUSCLE; SKIN; SKIN FIBROBLAST; SYMPTOMATOLOGY; SYSTEMIC SCLEROSIS;

ANIMALS; ANTIMETABOLITES; BLEOMYCIN; FEMALE; FIBROSIS; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HEPATOCYTE GROWTH FACTOR; HUMANS; INJECTIONS, INTRAMUSCULAR; LIPOSOMES; LUNG; MICE; MICE, INBRED C3H; MODELS, ANIMAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SCLERODERMA, LOCALIZED; SCLERODERMA, SYSTEMIC; SENDAI VIRUS; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA;

ANIMALIA; MURINAE; SCLERODERMA; SENDAI VIRUS;

EID: 0742306757     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302165     Document Type: Article

References (36)

1. Krieg T, Meurer M. Systemic scleroderma. Clinical and pathophysiological aspects. J Am Acad Dermatol 1988; 18: 457-481.
2. LeRoy EC. A brief overview of the pathogenesis of scleroderma (systemic sclerosis). Ann Rheum Dis 1992; 51: 286-288.
3. Jimenez SA, Christner P. Animal models of systemic sclerosis. Clin Dermatol 1994; 12: 425-436.
4. Umezawa H, Maeda K, Takeuchi T, Okami Y. New antibiotics, bleomycin A and B. J Antibiot (Tokyo) 1996; 19: 200-209.
5. Cohen IS et al. Cutaneous toxicity of bleomycin therapy. Arch Dermatol 1973; 107: 553-555.
6. Finch WR et al. Bleomycin-induced scleroderma. J Rheumatol 1980; 7: 651-659.
7. Nixon DW, Pirozzi D, York RM. Dermatologic changes after systemic cancer therapy. Cutis 1981; 27: 181-194.
8. Yamamoto T, Yokozeki H, Nishioka K. Dermal sclerosis in the lesional skin of 'flagellate' erythema (scratch dermatitis) induced by bleomycin. Dermatology 1998; 197: 399-400.
9. Adamson IVR, Bowden DH. The pathogenesis of bleomycin-induced pulmonary fibrosis in mice. Am J Pathol 1974; 77: 185-198.
10. Chandler DB. Possible mechanisms of bleomycin-induced pulmonary fibrosis in mice. Clin Chest Med 1990; 11: 21-30.
11. Yamamoto T et al. Animal model of sclerotic skin. I. Repeated injections of bleomycin induce dermal sclerosis mimicking scleroderma. J Invest Dermatol 1999; 112: 456-462.
12. v mice. J Rheumatol 1999; 26: 2628-2634.
13. Yamamoto T, Takagawa S, Kuroda M, Nishioka K. Effect of interferon-γ on experimental scleroderma induced by bleomycin. Arch Dermatol Res 2000; 292: 362-365.
14. Yamamoto T, Takagawa S, Katayama I, Nishioka K. Antisclerotic effect of transforming growth factor-β antibody in a mouse model of bleomycin-indued scleroderma. Clin Immunol 1999; 92: 6-13.
15. Nakamura T, Nawa K, Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun 1984; 122: 1450-1459.
16. Nakamura T. Molecular cloning and expression of human hepatocytes growth factor. Nature 1989; 342: 440-443.
17. Kawada K, Matsumoto K, Shimuzu H, Nakamura T. Hepatocyte growth factor prevents acute renal failure and accelerates renal regulation in mice. Proc Natl Acad Sci USA 1994; 91: 4357-4361.
18. Ohmichi H, Matsumoto K, Nakamura T. In vivo mitogenic action of HGF on lung epithelial cells: pulmotrophic roles in lung regeneration. Am J Physiol 1996; 14: L1031-L1039.
19. Kato Y, Yu D, Lukish JR, Schwart MZ. Influence of luminar hepatocyte growth factor on small intestine mucosa in vivo. J Surg Res 1997; 71: 49-53.
20. Bardelli A. HGF receptor associates with anti-apoptotic protein BAG-1 and prevents cell death. EMBO J 1996; 15: 6205-6212.
21. Kmiecik TE, Keller JR, Rosen E, Vande Woude GF. Hepatocyte growth factor is a synergistic factor for the growth of hematopoietic progenitor cells. Blood 1992; 80: 2454-2457.
22. Matsuda Y, Matsumoto K, Ichida T, Nakamura T. Hepatocyte growth factor prevents liver cirrhosis caused by dimethylnitrosamine in rats. J Biochem 1995; 118: 643-649.
23. Saeki Y et al. Development and characterization of cationic liposomes conjugated with HVJ (Sendai virus): reciprocal effect of cationic lipid for in vitro and in vivo gene transfer. Human Gene Therapy 1997; 20: 2133-2141.
24. Ueki T et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 1999; 5: 226-230.
25. Hayashi S-I et al. Autocrine-paracrine effects of overexpression of hepatocyte growth factor gene on growth of endothelial cells. Biochem Biophys Res Commun 1996; 220: 539-545.
26. Mizuno S, Matsumoto K, Kurosawa T, Okamoto M. Reciprocal balance of hepatocyte growth factor and transforming growth factor-β1 in renal fibrosis in mice. Kidney Int 2000; 57: 937-948.
27. Mizuno S et al. Hepatocyte growth factor prevents renal fibrosis and dysfunction in a mouse model of chronic renal disease. J Clin Invest 1998; 101: 1827-1834.
28. Yasuda HE et al. Antifibrogenesis effect of a deletion variant of hepatocyte growth factor on liver fibrosis in rats. Hepatology 1996; 24: 636-642.
29. Uehara Y et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 1995; 373: 702-705.
30. Matsumoto K, Kagoshima M, Nakamura T. Hepatocyte growth factor as a potent survival factor for rat pheochromocytoma PC12 cells. Exp Cell Res 1995; 220: 71-78.
31. Liu Y, Rajur K, Tolbert E, Dworkin D. Endogeneous hepatocyte growth factor ameliorates chronic renal injury by activating matrix degradation pathway. Kidney Int 2000; 58: 2028-2043.
32. Yaekashiwa M et al. Simultaneous or delayed administration of hepatocyte growth factor represses the fibrotic changes in murine lung injury by bleomycin. Am J Respir Crit Vare Med 1997; 156: 1937-1944.
33. Tsuboniwa N et al. Safety evaluation of HVJ-AVE liposomes in nonhuman primates. Hum Gene Ther 2001; 12: 469-487.
34. Isaka Y et al. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med 1996; 2: 418-423.
35. Shimaoka S, Imai R, Ogawa H. Dermal papilla cells express hepatocyte growth factor. J Dermatol Sci 1994; 7: s79-s83.
36. Mizuno S, Matsumoto K, Nakamura T. Hepatocyte growth factor suppresses interstitial fibrosis in a mouse model of obstructive nephropathy. Kidney Int 2001; 59: 1304-1314.